BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Vaccines

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

AcadeMab's treatment specifically targets the SARS-CoV-2 Omicron variant – currently the most common strain of COVID infections around the world. "I...

May 30, 2022 | News

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

In addition to shortening the vaccination cycle by leveraging the advantages of its single-dose regimen, Convidecia™ can be stably transported and st...

May 20, 2022 | News

ASEAN to build its own CDC to mitigate another pandemic risk

Indonesian Health Minister Budi Gunadi Sadikin said that Southeast Asia's regional bloc agreed to solidify the three main pillars of pa...

May 18, 2022 | News

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

As disclosed in the prospectus of the Company dated March 21, 2022, the Group had initiated subject enrollment for the phase II/III clinical trial for...

May 06, 2022 | News

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone....

April 30, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

April 28, 2022 | News

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed in...

April 22, 2022 | News

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious dise...

April 20, 2022 | News

Novavax and SII Receive EUA for Novavax' COVID-19 Vaccine in Thailand

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectiou...

April 11, 2022 | News

CR Pharma intends to make strategic equity investment for Everest's mRNA technology platform

Partnership with CR Pharma will provide local support to navigate China regulatory pathways across mRNA vaccine platform, first in the advancemen...

April 07, 2022 | News

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

April 05, 2022 | News

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

April 04, 2022 | News

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the EU to Adolescents (Ages 12-17)

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious dise...

April 01, 2022 | News

BioVaxys Expands Cancer Vaccine Platform

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platf...

March 31, 2022 | News

Stay Connected